Sclerostin

an Emerging Target for the Treatment of Cancer-Induced Bone Disease

Michelle M. McDonald, Jesus Delgado-Calle

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose of Review: This review provides a summary of the current knowledge on Sost/sclerostin in cancers targeting the bone, discusses novel observations regarding its potential as a therapeutic approach to treat cancer-induced bone loss, and proposes future research needed to fully understand the potential of therapeutic approaches that modulate sclerostin function. Recent Findings: Accumulating evidence shows that sclerostin expression is dysregulated in a number of cancers that target the bone. Further, new findings demonstrate that pharmacological inhibition of sclerostin in preclinical models of multiple myeloma results in a robust prevention of bone loss and preservation of bone strength, without apparent effects on tumor growth. These data raise the possibility of targeting sclerostin for the treatment of cancer patients with bone metastasis. Summary: Sclerostin is emerging as a valuable target to prevent the bone destruction that accompanies the growth of cancer cells in the bone. Further studies will focus on combining anti-sclerostin therapy with tumor-targeted agents to achieve both beneficial skeletal outcomes and inhibition of tumor progression.

Original languageEnglish (US)
Pages (from-to)1-10
Number of pages10
JournalCurrent Osteoporosis Reports
DOIs
StateAccepted/In press - Sep 27 2017

Fingerprint

Bone Neoplasms
Bone Diseases
Bone and Bones
Neoplasms
Therapeutics
Growth
Multiple Myeloma
Pharmacology
Neoplasm Metastasis

Keywords

  • Bone
  • Cancer
  • Myeloma
  • Osteoblasts
  • Osteoclasts
  • Sost/sclerostin

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Sclerostin : an Emerging Target for the Treatment of Cancer-Induced Bone Disease. / McDonald, Michelle M.; Delgado-Calle, Jesus.

In: Current Osteoporosis Reports, 27.09.2017, p. 1-10.

Research output: Contribution to journalArticle

@article{f65787a632c146a099e7c57c91d101fd,
title = "Sclerostin: an Emerging Target for the Treatment of Cancer-Induced Bone Disease",
abstract = "Purpose of Review: This review provides a summary of the current knowledge on Sost/sclerostin in cancers targeting the bone, discusses novel observations regarding its potential as a therapeutic approach to treat cancer-induced bone loss, and proposes future research needed to fully understand the potential of therapeutic approaches that modulate sclerostin function. Recent Findings: Accumulating evidence shows that sclerostin expression is dysregulated in a number of cancers that target the bone. Further, new findings demonstrate that pharmacological inhibition of sclerostin in preclinical models of multiple myeloma results in a robust prevention of bone loss and preservation of bone strength, without apparent effects on tumor growth. These data raise the possibility of targeting sclerostin for the treatment of cancer patients with bone metastasis. Summary: Sclerostin is emerging as a valuable target to prevent the bone destruction that accompanies the growth of cancer cells in the bone. Further studies will focus on combining anti-sclerostin therapy with tumor-targeted agents to achieve both beneficial skeletal outcomes and inhibition of tumor progression.",
keywords = "Bone, Cancer, Myeloma, Osteoblasts, Osteoclasts, Sost/sclerostin",
author = "McDonald, {Michelle M.} and Jesus Delgado-Calle",
year = "2017",
month = "9",
day = "27",
doi = "10.1007/s11914-017-0403-y",
language = "English (US)",
pages = "1--10",
journal = "Current Osteoporosis Reports",
issn = "1544-1873",
publisher = "Current Science, Inc.",

}

TY - JOUR

T1 - Sclerostin

T2 - an Emerging Target for the Treatment of Cancer-Induced Bone Disease

AU - McDonald, Michelle M.

AU - Delgado-Calle, Jesus

PY - 2017/9/27

Y1 - 2017/9/27

N2 - Purpose of Review: This review provides a summary of the current knowledge on Sost/sclerostin in cancers targeting the bone, discusses novel observations regarding its potential as a therapeutic approach to treat cancer-induced bone loss, and proposes future research needed to fully understand the potential of therapeutic approaches that modulate sclerostin function. Recent Findings: Accumulating evidence shows that sclerostin expression is dysregulated in a number of cancers that target the bone. Further, new findings demonstrate that pharmacological inhibition of sclerostin in preclinical models of multiple myeloma results in a robust prevention of bone loss and preservation of bone strength, without apparent effects on tumor growth. These data raise the possibility of targeting sclerostin for the treatment of cancer patients with bone metastasis. Summary: Sclerostin is emerging as a valuable target to prevent the bone destruction that accompanies the growth of cancer cells in the bone. Further studies will focus on combining anti-sclerostin therapy with tumor-targeted agents to achieve both beneficial skeletal outcomes and inhibition of tumor progression.

AB - Purpose of Review: This review provides a summary of the current knowledge on Sost/sclerostin in cancers targeting the bone, discusses novel observations regarding its potential as a therapeutic approach to treat cancer-induced bone loss, and proposes future research needed to fully understand the potential of therapeutic approaches that modulate sclerostin function. Recent Findings: Accumulating evidence shows that sclerostin expression is dysregulated in a number of cancers that target the bone. Further, new findings demonstrate that pharmacological inhibition of sclerostin in preclinical models of multiple myeloma results in a robust prevention of bone loss and preservation of bone strength, without apparent effects on tumor growth. These data raise the possibility of targeting sclerostin for the treatment of cancer patients with bone metastasis. Summary: Sclerostin is emerging as a valuable target to prevent the bone destruction that accompanies the growth of cancer cells in the bone. Further studies will focus on combining anti-sclerostin therapy with tumor-targeted agents to achieve both beneficial skeletal outcomes and inhibition of tumor progression.

KW - Bone

KW - Cancer

KW - Myeloma

KW - Osteoblasts

KW - Osteoclasts

KW - Sost/sclerostin

UR - http://www.scopus.com/inward/record.url?scp=85030088169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030088169&partnerID=8YFLogxK

U2 - 10.1007/s11914-017-0403-y

DO - 10.1007/s11914-017-0403-y

M3 - Article

SP - 1

EP - 10

JO - Current Osteoporosis Reports

JF - Current Osteoporosis Reports

SN - 1544-1873

ER -